Consult Wing-Zero Friction Discussion

Why Combination Products Stall When the Device Comes Last

Drug teams often pick a delivery device from a catalog and deal with the fallout later. How should combination product teams plan for risk?

We frame risk management for combination products around three Ps.

  • Product: risk from design through manufacturing, including how it is packaged, stored and delivered.
  • Practitioner: what the labeling tells clinicians about known failures and anything that could not be mitigated in development.
  • Patient: what the patient will understand, especially when they deliver the drug themselves.

Drug companies tend to focus on adverse events and toxicology. Paul agrees that is the core risk. What gets missed, in his view, is the rest of the process.

He also says regulators, including the FDA, are bringing quality systems on the device and drug sides into line. Check out the whole discussion at this link:

https://www.revrxai.com/insights/combination-products-device-planning-paul-landesman